17β-estradiol and progesterone monotherapies have the same anticancer effects and enhance the tumor-killing effects of CRC in men through the promotion of androgen deprivation mediated by ERβ and PGR, while also blocking oncogenic pathways regulated by ERα (68). Here, PGR is linked to neoplasm.